Search results
Results from the WOW.Com Content Network
An asymptomatic carrier is a person or other organism that has become infected with a pathogen, but shows no signs or symptoms. [ 1 ] Although unaffected by the pathogen, carriers can transmit it to others or develop symptoms in later stages of the disease.
Subclinical infections can occur in both humans and animals. [2] Depending on the pathogen, which can be a virus or intestinal parasite, the host may be infectious and able to transmit the pathogen without ever developing symptoms; [3] [4] such a host is called an asymptomatic carrier. [3]
In August 2020, the U.S. Food and Drug Administration (FDA) became aware of nitrosamine impurities in certain samples of rifampin. [61] The FDA and manufacturers are investigating the origin of these impurities in rifampin, and the agency is developing testing methods for regulators and industry to detect the 1-methyl-4-nitrosopiperazine (MNP ...
In these kinds of cases with a significant number of pre-symptomatic (asymptomatic) transmissions, symptomatic surveillance-based disease control measures (such as isolation, contact tracing, enhanced hygiene, etc.) are likely to have their effectiveness reduced, because a significant portion of the transmission may take place before the onset ...
In epidemiology, force of infection (denoted ) is the rate at which susceptible individuals acquire an infectious disease. [1] Because it takes account of susceptibility it can be used to compare the rate of transmission between different groups of the population for the same infectious disease, or even between different infectious diseases.
Rifampin rapidly kills fast-dividing bacilli strains as well as "persisters" cells, which remain biologically inactive for long periods of time that allow them to evade antibiotic activity. [7] In addition, rifabutin and rifapentine have both been used against tuberculosis acquired in HIV-positive patients.
Management of tuberculosis refers to techniques and procedures utilized for treating tuberculosis (TB), or simply a treatment plan for TB.. The medical standard for active TB is a short course treatment involving a combination of isoniazid, rifampicin (also known as Rifampin), pyrazinamide, and ethambutol for the first two months.
In non-resistant TB, rifampin binds the beta subunit of RNA polymerase and disrupts transcription elongation. Mutation in the rpoB gene changes the sequence of amino acids and eventual conformation, or arrangement, of the beta subunit. In this case, rifampin can no longer bind or prevent transcription, and the bacterium is resistant. [19] [20]